We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.75B Turnover 23.84%
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8 years
Top 10 Avg Time Held
2.6 years
Top 20 Avg Time Held
2.5 years

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD icon
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Miscellaneous 0.05%
5 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TNGX icon
26
Tango Therapeutics
TNGX
$3.83B
$50.2M 1.19%
2,400,000
-1,527,670
-39% -$21.3M
2025 Q4
1 quarter
IDXX icon
27
Idexx Laboratories
IDXX
$43.1B
$50.1M 1.19%
89,131
-5,408
-6% -$3.47M
2018 Q2
31 quarters
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$1.5B
$49.9M 1.19%
2,380,000
+2,377,420
+92,148% +$53.5M
2025 Q4
1 quarter
DXCM icon
29
DexCom
DXCM
$33.1B
$49.5M 1.18%
788,766
-58,639
-7% -$4.08M
2016 Q4
37 quarters
JBIO icon
30
Jade Biosciences
JBIO
$875M
$49.2M 1.17%
3,501,502
+160,399
+5% +$2.32M
2025 Q4
1 quarter
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.15B
$48.1M 1.15%
1,528,518
– –
2024 Q2
7 quarters
UNH icon
32
UnitedHealth
UNH
$365B
$40.1M 0.95%
148,203
-26,966
-15% -$8.03M
2016 Q1
40 quarters
DHR icon
33
Danaher
DHR
$163B
$38.3M 0.91%
202,164
+7,531
+4% +$1.6M
2016 Q4
37 quarters
CLDX icon
34
Celldex Therapeutics
CLDX
$2.27B
$38.1M 0.91%
1,200,000
-2,417,669
-67% -$65.9M
2022 Q2
15 quarters
RMD icon
35
ResMed
RMD
$34.1B
$35.8M 0.85%
159,346
-1,868
-1% -$466K
2016 Q1
40 quarters
PODD icon
36
Insulet
PODD
$9.62B
$34.3M 0.82%
163,656
-23,043
-12% -$5.79M
2016 Q1
40 quarters
TMO icon
37
Thermo Fisher Scientific
TMO
$258B
$31.7M 0.75%
64,412
-665
-1% -$361K
2016 Q1
40 quarters
LLY icon
38
Eli Lilly
LLY
$1.12T
$31.2M 0.74%
33,932
-71
-0.2% -$72K
2022 Q2
15 quarters
GEHC icon
39
GE HealthCare
GEHC
$31.8B
$29.7M 0.71%
416,887
-7,627
-2% -$601K
2023 Q3
10 quarters
IRON icon
40
Disc Medicine
IRON
$2.17B
$29.4M 0.7%
+459,314
New +$31.9M
2026 Q1
0 quarters
JNJ icon
41
Johnson & Johnson
JNJ
$610B
$29.1M 0.69%
119,102
-7,698
-6% -$1.79M
2020 Q4
21 quarters
ANNX icon
42
Annexon
ANNX
$682M
$28.6M 0.68%
5,157,290
– –
2024 Q1
8 quarters
CI icon
43
Cigna
CI
$79B
$26.2M 0.62%
98,263
-11,750
-11% -$3.25M
2016 Q1
40 quarters
ORKA icon
44
Oruka Therapeutics
ORKA
$4.89B
$24.9M 0.59%
+507,008
New +$17.6M
2026 Q1
0 quarters
MRK icon
45
Merck
MRK
$358B
$24.9M 0.59%
206,591
+114,474
+124% +$13.2M
2022 Q2
15 quarters
ALGN icon
46
Align Technology
ALGN
$10.6B
$23.9M 0.57%
139,680
-1,794
-1% -$314K
2017 Q1
36 quarters
STE icon
47
Steris
STE
$21.9B
$22.1M 0.53%
99,878
-1,827
-2% -$447K
2024 Q1
8 quarters
GMED icon
48
Globus Medical
GMED
$10.6B
$21.3M 0.51%
247,261
-15,422
-6% -$1.38M
2016 Q1
40 quarters
GLUE icon
49
Monte Rosa Therapeutics
GLUE
$863M
$20.6M 0.49%
+1,250,000
New +$23.9M
2026 Q1
0 quarters
ABBV icon
50
AbbVie
ABBV
$501B
$20.3M 0.48%
93,567
-41,292
-31% -$9.16M
2019 Q4
25 quarters
1
2
3 4 5

Similar funds

Stockbridge Partners
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GTS Securities
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SONA Asset Management (US)
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
Local Pensions Partnership Investment
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
Nicholas Hoffman & Company
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Truepoint Inc
Truepoint Inc Cincinnati, Ohio $4.79B AUM 16.42% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.